Table 2.
Individual studies with sample sizes and types of cardiomyopathy
| Study | Sample size |
CMR | Findings |
| Goebel et al.18 2016 |
150 | T1 mapping CMR |
Does not differentiate healthy and diffusely diseased myocardium |
| Makoto et al.19 2016 |
44 | LGE CMR | LE in CS predominantly basal, mid septum and throughout the LV, while in DCM, LE was localized in the basal and mid septum |
| Mikami et al.20 2016 |
118 | LGE CMR | Septal fibrosis |
| Okada et al.21 2016 |
102 | LGE CMR | TIC had a significant lower RVEF, and a larger RVEDV and RVEDS |
| Kwong et al.22 2015 |
81 | Cine SSFP and LGE |
CA mean proportion of atrial enhancement was significantly greater compared to SH and NIDCM |
| Maurizio et al.23 2015 |
77 | LGE CMR | Hypertrophied septum indicating regional fibrosis in HCM |
| Schwab et al.24 2015 |
43 | CMR | Wall motion abnormalities |
| Nguyen et al.25 2015 |
23 | CMR/LGE CMR |
Diffuse myocardial fibrosis |
| Dungu et al.26 2013 |
97 | LGE CMR | Distinguished ATTR from AL cardiac amyloidosis |
| Ferreira et al.27 2013 |
50 | T1 mapping CMR |
T1 mapping is a criterion for detection of acute myocarditis with a higher sensitivity |
| Choi et al.28 2016 |
114 | Cine CMR/ LGE CMR |
Classification of distribution of trabeculation, 43.9% global type, 56.2% apical type |
| Gulsin et al.29 2017 |
100 | Cine CMR/ LGE CMR |
Global LV hypokinesis |
Abbreviations: CMR= cardiac magnetic resonance, LGE= late gadolinium enhancement, LE= late enhancement, CS= cardiac sarcoidosis, DCM= dilated cardiomyopathy, TIC= tachycardia induced cardiomyopathy, RVEDV= right ventricle end diastolic volume, RVEDS= right ventricle end systolic volume, CA= cardiac amyloidosis, SH= systemic hypertension, NIDCM= Nonischemic dilated cardiomyopathy, HCM= hypertrophic cardiomyopathy, AL= amyloid light chain, ATTR= transthyretin related Amyloidosis, SSFP= steady state free precision